PT  - JOURNAL ARTICLE
AU  - HIND RAFEI
AU  - EHAB EL-BAHESH
AU  - ANTOINE FINIANOS
AU  - SAMAH NASSEREDDINE
AU  - IMAD TABBARA
TI  - Immune-based Therapies for Non-small Cell Lung Cancer
DP  - 2017 Feb 01
TA  - Anticancer Research
PG  - 377--387
VI  - 37
IP  - 2
4099  - http://ar.iiarjournals.org/content/37/2/377.short
4100  - http://ar.iiarjournals.org/content/37/2/377.full
SO  - Anticancer Res2017 Feb 01; 37
AB  - Lung cancer is the leading cause of cancer-related death worldwide. Treatment of non-small cell lung cancer has evolved tremendously over the past decade. Specifically, immune checkpoint inhibitors have become an increasingly interesting target of pharmacological blockade. These immune inhibitors have shown promising results in front-line therapy and after failure of multiple lines, as well as in monotherapy and combination with other therapies. Vaccination in non-small cell lung cancer is also an emerging field of research that holds promising results for the future of immunotherapy in non-small cell lung cancer. This review presents a concise update on the most recent data regarding the role of checkpoint inhibitors as well as vaccination in non-small cell lung cancer.